vaccination targeting a surface sialidase of p. acnes implication for new treatment of acne vulgaris疫苗接种目标表面唾液酸酶pu2022曼秀雷敦新治疗寻常痤疮的含义.pdfVIP

Vaccination Targeting a Surface Sialidase of P. acnes: Implication for New Treatment of Acne Vulgaris 1,2 3 2,3 1,2 1,2,3,4 Teruaki Nakatsuji , Yu-Tsueng Liu , Cheng-Po Huang , Richard L. Gallo , Chun-Ming Huang * 1 Division of Dermatology, Department of Medicine, University of California San Diego, San Diego, California, United States of America, 2 Veterans Affairs (VA) San Diego Healthcare Center, San Diego, California, United States of America, 3 Moores Cancer Center, University of California San Diego, San Diego, California, United States of America, 4 La Jolla Institute for Molecular Medicine, San Diego, California, United States of America Abstract Background: Acne vulgaris afflicts more than fifty million people in the United State and the severity of this disorder is associated with the immune response to Propionibacterium acnes (P. acnes). Systemic therapies for acne target P. acnes using antibiotics, or target the follicle with retinoids such as isotretinoin. The latter systemic treatment is highly effective but also carries a risk of side effects including immune imbalance, hyperlipidemia, and teratogenicity. Despite substantial research into potential new therapies for this common disease, vaccines against acne vulgaris are not yet available. Methods and Findings: Here we create an acne vaccine targeting a cell wall-anchored sialidase of P. acnes. The importance of sialidase to disease pathogenesis is shown by treatment of a human sebocyte cell line with recombinant sialidase that increased susceptibility to P. acnes cytotoxicity and adhesion. Mice immunized with sialidase elicit a detectable antibody; the anti-sialidase serum effectiv